Schering-Plough to close plant.
Schering-Plough Corp. is cutting 1,100 jobs, closing one plant in
Puerto Rico and streamlining operations at other plants there and in New
Jersey, reports Bloomberg (June 2, 2006). The plant at Manati, Puerto
Rico, will close by the end of 2006, the company said. Schering-Plough,
developer of the Claritin and Clarinex allergy drugs, has been working
on a turnaround program since Claritin lost patent protection in 2002,
leading to three years of losses. About 550 full-time positions will be
eliminated at the Manati plant, which makes Nasonex, an allergy spray,
and Afrin, an over-the-counter decongestant. A further 50 jobs will be
cut at a plant in Las Piedras, Puerto Rico, which will continue to
operate, employing 475 people. That plant makes Zetia, for cholesterol
control; Clarinex, an allergy medication; and Rebetol, for hepatitis B.